Home Duke University Press
 QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


First published on June 16, 2008
This version was published on August 1, 2008
Neuro Oncol 2008 10(4):577-582; DOI:10.1215/15228517-2008-025
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
10/4/577    most recent
15228517-2008-025v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sirachainan, N.
Right arrow Articles by Hongeng, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Duke University Press

Clinical Investigations

Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma

Nongnuch Sirachainan, Samart Pakakasama, Anannit Visudithbhan, Surang Chiamchanya, Lojana Tuntiyatorn, Mantana Dhanachai, Jiraporn Laothamatas and Suradej Hongeng

Departments of Pediatrics (N.S., S.P., A.V., S.C., S.H.) and Radiology (L.T., M.D., J.L.), Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Address all correspondence to Suradej Hongeng, Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Rama VI Rd., Bangkok 10400, Thailand (rashe{at}mahidol.ac.th).

The prognosis of children with diffuse intrinsic pontine glioma (DIPG) is very poor. Radiotherapy remains the standard treatment for these patients, but the median survival time is only 9 months. Currently, the use of concurrent radiotherapy with temozolomide (TMZ) has become the standard care for adult patients with malignant gliomas. We therefore investigated this approach in 12 children diagnosed with DIPG. The treatment protocol consisted of concurrent radiotherapy at a dose of 55.8-59.4 Gy at the tumor site with TMZ (75 mg/m2/day) for 6 weeks followed by TMZ (200 mg/m2/day) for 5 days with cis-retinoic acid (100 mg/m2/day) for 21 days with a 28-day cycle after concurrent radiotherapy. Ten of the 12 patients had a clinical response after the completion of concurrent radiotherapy. Seven patients had a partial response, four had stable disease, and one had progressive disease. At the time of the report, 9 of the 12 patients had died of tumor progression, one patient was alive with tumor progression, and two patients were alive with continuous partial response and clinical improvement. The median time to progression was 10.2 ± 3.0 months (95% confidence interval [CI], 4.2-16.1 months). One-year progression-free survival was 41.7% ± 14.2%. The median survival time was 13.5 ± 3.6 months (95% CI, 6.4-20.5 months). One-year overall survival was 58% ± 14.2%. The patients who had a partial response after completion of concurrent radiotherapy had a longer survival time (p = 0.036) than did the other patients (those with stable or progressive disease). We conclude that the regimen of concurrent radiotherapy and TMZ should be considered for further investigation in a larger series of patients.

Key Words: children • cis-retinoic acid • concurrent radiotherapy • diffuse intrinsic pontine glioma • temozolomide


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents


Copyright 2008 by Society for Neuro-Oncology